PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21106989-0	2011	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.	tofacitinib	0-6	Janus kinase 3	Homo sapiens	60-64	
21106989-0	2011	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.	tofacitinib	0-6	thrombospondin 1	Homo sapiens	136-139	
21106989-3	2011	We evaluated the action of the Jak3 inhibitor CP-690,550 on cytokine dependent ex vivo proliferation that is characteristic of peripheral blood mononuclear cells (PBMCs) from select patients with smoldering or chronic subtypes of ATL, or from those with HAM/TSP whose PBMCs are associated with autocrine/paracrine pathways that involve the production of IL-2, IL-9, IL-15, and their receptors.	tofacitinib	46-52	Janus kinase 3	Homo sapiens	31-35	
21106989-3	2011	We evaluated the action of the Jak3 inhibitor CP-690,550 on cytokine dependent ex vivo proliferation that is characteristic of peripheral blood mononuclear cells (PBMCs) from select patients with smoldering or chronic subtypes of ATL, or from those with HAM/TSP whose PBMCs are associated with autocrine/paracrine pathways that involve the production of IL-2, IL-9, IL-15, and their receptors.	tofacitinib	46-52	thrombospondin 1	Homo sapiens	258-261	
21106989-3	2011	We evaluated the action of the Jak3 inhibitor CP-690,550 on cytokine dependent ex vivo proliferation that is characteristic of peripheral blood mononuclear cells (PBMCs) from select patients with smoldering or chronic subtypes of ATL, or from those with HAM/TSP whose PBMCs are associated with autocrine/paracrine pathways that involve the production of IL-2, IL-9, IL-15, and their receptors.	tofacitinib	46-52	interleukin 2	Homo sapiens	354-358	
21106989-3	2011	We evaluated the action of the Jak3 inhibitor CP-690,550 on cytokine dependent ex vivo proliferation that is characteristic of peripheral blood mononuclear cells (PBMCs) from select patients with smoldering or chronic subtypes of ATL, or from those with HAM/TSP whose PBMCs are associated with autocrine/paracrine pathways that involve the production of IL-2, IL-9, IL-15, and their receptors.	tofacitinib	46-52	interleukin 9	Homo sapiens	360-364	
21106989-3	2011	We evaluated the action of the Jak3 inhibitor CP-690,550 on cytokine dependent ex vivo proliferation that is characteristic of peripheral blood mononuclear cells (PBMCs) from select patients with smoldering or chronic subtypes of ATL, or from those with HAM/TSP whose PBMCs are associated with autocrine/paracrine pathways that involve the production of IL-2, IL-9, IL-15, and their receptors.	tofacitinib	46-52	interleukin 15	Homo sapiens	366-371	
21106989-4	2011	CP-690,550 at 50 nM inhibited the 6-day ex vivo spontaneous proliferation of PBMCs from ATL and HAM/TSP patients by 67.1% and 86.4%, respectively.	tofacitinib	0-6	thrombospondin 1	Homo sapiens	100-103	
21106989-5	2011	Furthermore, CP-690,550 inhibited STAT5 phosphorylation in isolated ATL T cells ex vivo.	tofacitinib	13-19	signal transducer and activator of transcription 5A	Homo sapiens	34-39	
21106989-6	2011	Finally, in an in vivo test of biological activity, CP-690,550 treatment of mice with a CD8 T-cell IL-15-transgenic leukemia that manifests an autocrine IL-15/IL-15Ralpha pathway prolonged the survival duration of these tumor-bearing mice.	tofacitinib	52-58	interleukin 15	Mus musculus	99-104	
21106989-6	2011	Finally, in an in vivo test of biological activity, CP-690,550 treatment of mice with a CD8 T-cell IL-15-transgenic leukemia that manifests an autocrine IL-15/IL-15Ralpha pathway prolonged the survival duration of these tumor-bearing mice.	tofacitinib	52-58	interleukin 15	Mus musculus	153-158	
21106989-6	2011	Finally, in an in vivo test of biological activity, CP-690,550 treatment of mice with a CD8 T-cell IL-15-transgenic leukemia that manifests an autocrine IL-15/IL-15Ralpha pathway prolonged the survival duration of these tumor-bearing mice.	tofacitinib	52-58	interleukin 15 receptor, alpha chain	Mus musculus	159-170	
21106989-7	2011	These studies support further evaluation of the Jak3 inhibitor CP-690,550 in the treatment of select patients with HTLV-I-associated ATL and HAM/TSP.	tofacitinib	63-69	Janus kinase 3	Homo sapiens	48-52	
21106989-7	2011	These studies support further evaluation of the Jak3 inhibitor CP-690,550 in the treatment of select patients with HTLV-I-associated ATL and HAM/TSP.	tofacitinib	63-69	thrombospondin 1	Homo sapiens	145-148